From: Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation
Characteristic | Full Sample (N = 598) |
---|---|
All respondents | |
Age, mean (SD), years | 40.9 (8.2) |
Age 40 years or older | 335 (56%) |
Has children | 416 (70%) |
Hopes to have children in future (after mutation identified) or undecideda | 268 (45%) |
White or Caucasian | 558 (93%) |
Married/living as married/civil partnership | 440 (74%) |
Higher education (defined as post-secondary/any college and higher) | 401 (67%) |
Employed full time | 329 (55%) |
Country of residence | |
United States | 331 (55%) |
United Kingdom | 117 (20%) |
Australia | 119 (20%) |
Canada | 31 (5%) |
Mutation | |
BRCA1 | 310 (52%) |
BRCA2 | 273 (46%) |
BRCA1 and BRCA2 | 8 (1%) |
Don’t know or not sure | 7 (1%) |
Mean time since genetic test, years (SD) | 4.8 (4.3) |
First degree relative with breast cancer | 374 (63%) |
First degree relative with ovarian cancer | 122 (20%) |
Risk-reducing treatments | |
RRBM only | 95 (16%) |
RRBSO only | 112 (19%) |
RRBM and RRBSO | 198 (33%) |
Has taken a prescription medication, such as tamoxifen, raloxifene, or an aromatase inhibitor [anastrazole, exemestane] | 33 (6%) |
Among women who did not report RRBM surgery | |
n | 305 |
Very likely or somewhat likely to undergo RRBM in the futureb | 193 (63%) |
Among women who did not report RRBSO surgery | |
n | 288 |
Very likely or somewhat likely to undergo RRBSO in the futurec | 255 (89%) |
All respondents | |
nd | 587 |
Assigned to Susan, age 25 years | 285 (48%) |
Assigned to Susan, age 36 years | 302 (51%) |